Drug Therapy to Treat Minor Depression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

73 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-02-28

Study Completion Date

2007-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This 6-month study will compare the effectiveness of citalopram (Celexa®), hypericum (St. John's Wort), and placebo for the treatment of minor depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Major Depression With St. John's Wort (Hypericum)

NCT00005013

Major Depression

COMPLETED NA

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445

Major Depressive Disorder Depression

COMPLETED PHASE2

Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects

NCT00001919

Healthy Mood Disorder

COMPLETED

Citalopram vs Clomipramine vs Placebo in Recurrent Depression

NCT01575158

Depression

COMPLETED NA

Low Dose St John's Wort for Depression

NCT05477472

Major Depression

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Minor depression is highly prevalent, causes substantial morbidity and disability, presents a serious risk factor for the development of major depressive disorder, yet is under recognized and under treated. Researchers have determined that patients with minor depression frequently seek treatment from general practitioners and are often treated with prescription antidepressants. There is a need to evaluate the effectiveness of St. John's Wort in the management of minor depression. If the proposed study demonstrates the efficacy of St. John's Wort and/or citalopram, it will suggest treatment paradigms that can be tested and applied in primary care settings.

Subjects participated in a 12-week double-blind randomized study comparing St. John's Wort, citalopram, and placebo. Subjects were recruited through clinical referrals and community advertising. Data were obtained at the baseline visit (just prior to randomization) and at postrandomization visits conducted at 2-week intervals for the next 12 weeks, for a modified intent-to-treat sample consisting of all 73 subjects with at least 1 post-randomization visit (evaluable sample).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

citalopram

Subjects in this arm received 20mg/day of citalopram taken orally for 12 weeks.

Group Type ACTIVE_COMPARATOR

Citalopram

Intervention Type DRUG

Established Selective Serotonin Reuptake Inhibitor antidepressant

St. John's Wort

Subjects in this arm received 810 mg/day of St. John's Wort taken orally (in three tablets of 270mg each) for 12 weeks.

Group Type EXPERIMENTAL

St. John's Wort

Intervention Type DRUG

Natural extract from the St. John's Wort plant.

Placebo

Subjects in this arm received double-dummy (look-alike) placebo for 12 weeks.

Group Type PLACEBO_COMPARATOR

Placebos

Intervention Type DRUG

Placebo pill

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Citalopram

Established Selective Serotonin Reuptake Inhibitor antidepressant

Intervention Type DRUG

St. John's Wort

Natural extract from the St. John's Wort plant.

Intervention Type DRUG

Placebos

Placebo pill

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Celexa, Cipramil Hypericum

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Minor Depression symptoms for at least 6 months
* Endorse one of the DSM-IV "A" criteria for MDD and at least one other symptom of MDD or endorse both of the "A" criteria for MDD
* Global Assessment of Functioning (GAF) score \< 70
* Short form health survey (SF-36) social functioning score \<= 75% or an emotional role functioning score \<= 67%
* HAM-D-17 score 10-17, inclusive
* Minor depression symptoms for at least 6 months

Exclusion Criteria

* Major depressive disorder (MDD) or dysthymia within the past year or in partial remission of MDD
* At least a 12-week course of either citalopram at a minimum or 40 mg/day or St. John's Wort at a minimum of 900 mg/day during the current episode of depression
* Previous intolerance to either citalopram or St. John's Wort or history of nonresponse to either citalopram at a minimum of 40 mg/day or St. John's Wort at a minimum of 900 mg/day for at least 12 weeks
* Unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease
* Uncontrolled seizure disorder
* The following DSM-IV diagnoses: organic mental disorders; substance use disorders, including alcohol, active within the last year or patients with a positive urine drug screen; schizophrenia; delusional disorder; psychotic disorders not elsewhere classified; bipolar disorder; bereavement; adjustment disorder; antisocial personality disorder; panic disorder, social phobia, generalized anxiety disorder (GAD), or obsessive compulsive disorder (OCD). Patients may have a lifetime diagnosis of an anxiety disorder as long as it is not current.
* Mood-congruent or mood-incongruent psychotic features
* Psychotropic drugs
* Hypothyroidism
* Investigational psychotropic drugs within the last year
* Positive toxicology screen
* Medications metabolized by the CYP3A4 system, where induction of this system poses a risk to the medical stability of the patient
* Pregnancy or refusal to use a medically accepted method of contraception
* Serious suicide or homicide risk
* Psychotherapy beginning less than 3 months ago

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No